Molecular determinants of ovarian cancer chemoresistance: New insights into an old conundrum

Annals of the New York Academy of Sciences

Volumn 1271, Issue 1, 2012, Pages 58-67

  Ali, Ahmed Y ^a,b   Farrand, Lee ^c   Kim, Ji Young ^b,c   Byun, Sanguine ^c   Suh, Jeong Yong ^c   Lee, Hyong Joo ^c   Tsang, Benjamin K ^a,b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c Seoul National University   (South Korea)

Author keywords

Functional food compounds; Ovarian cancer chemoresistance; P53; PI3K Akt; PPM1D

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 2; CISPLATIN; CISPLATIN DERIVATIVE; CURCUMIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUTEOLIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P16; PROTEIN P19; PROTEIN P53; PUMA PROTEIN; RESVERATROL; TRANSCRIPTION FACTOR FKHR;

APOPTOSIS; ARTICLE; BROCCOLI; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL FATE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIZATION; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; FEMALE; FUNCTIONAL FOOD; G2 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GRAPE; HOMEOSTASIS; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE; OVARY CANCER; PREVENTIVE MEDICINE; PROTEIN PHOSPHATASE MAGNESIUM MANGANESE DEPENDENT 1 D GENE; PROTEIN PROTEIN INTERACTION; SEDENTARY LIFESTYLE; SIGNAL TRANSDUCTION; SMOKING; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84867434999     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06734.x     Document Type: Article

References (105)

1. http://www.cancer.ca. 2011.
2. Fraser, M. et al. 2003. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod. Biol. Endocrinol. 1: 66.
3. Woo, M.G. et al. 2012. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking. J. Biol. Chem. 287: 3963-3975.
4. Yang, X. et al. 2006. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 66: 3126-3136.
5. Abedini, M.R. et al. 2010. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 29: 11-25.
6. Yan, X. et al. 2006. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol. Oncol. 102: 348-355.
7. Fraser, M. et al. 2003. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res. 63: 7081-7088.
8. Fraser, M. et al. 2006. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells. Oncogene 25: 2203-2212.
9. Fraser, M., T. Bai & B.K. Tsang. 2008. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int. J. Cancer. 122: 534-546.
10. Abedini, M.R. et al. 2008. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res. 68: 4511-4517.
11. Ali, A.Y., M.R. Abedini & B.K. Tsang. 2012. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene 31: 2175-2186.
12. Jung, Y.S., Y. Qian & X. Chen. 2010. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal. 22: 1003-1012.
13. Peng, C.Y. et al. 1997. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277: 1501-1505.
14. Chan, T.A. et al. 1999. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620.
15. Park, S.Y., M.S. Jeong & S.B. Jang. In vitro binding properties of tumor suppressor p53 with PUMA and NOXA. Biochem. Biophys. Res. Commun. 420: 350-356.
16. Nakano, K. & K.H. Vousden. 2001. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7: 683-694.
17. Miyashita, T. & J.C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299.
18. Sax, J.K. et al. 2002. BID regulation by p53 contributes to chemosensitivity. Nat. Cell Biol. 4: 842-849.
19. Moroni, M.C., E.S. Hickman, E. Lazzerini Denchi, G. Caprara, E. Colli, et al. 2001. Apaf-1 is a transcriptional target for E2F and p53. Nat. Cell Biol. 3: 552-558.
20. Muller, M. et al. 1998. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188: 2033-2045.
21. Liu, X. et al. 2004. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 64: 5078-5083.
22. Wu, G.S., Burns, T.F., E.R. McDonald 3rd. et al. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17: 141-143.
23. Petitjean, A. et al. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28: 622-629.
24. Reinhardt, H.C. & B. Schumacher. 2012. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet. 28: 128-136.
25. Lu, X. et al. 2008. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 27: 123-135.
26. Fiscella, M. et al. 1997. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc. Natl. Acad. Sci. USA 94: 6048-6053.
27. Rossi, M. et al. 2008. Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites. Nucleic. Acids Res. 36: 7168-7180.
28. Lowe, J.M. et al. Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase. J. Biol. Chem. 285: 5249-5257.
29. Han, H.S. et al. 2009. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression. Mol. Cancer Res. 7: 713-723.
30. Hershko, T. et al. 2006. E2F1 modulates p38 MAPK phosphorylation via transcriptional regulation of ASK1 and Wip1. J. Biol. Chem. 281: 31309-31316.
31. Song, J.Y. et al. 2010. Expression of a homeostatic regulator, Wip1 (wild-type p53-induced phosphatase), is temporally induced by c-Jun and p53 in response to UV irradiation. J. Biol. Chem. 285: 9067-9076.
32. Yamaguchi, H. et al. 2007. The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases. Biochemistry 46: 12594-12603.
33. Lu, X., B. Nannenga & L.A. Donehower. 2005. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes. Dev. 19: 1162-1174.
34. Yamaguchi, H. et al. 2005. Substrate specificity of the human protein phosphatase 2Cdelta, Wip1. Biochemistry 44: 5285-5294.
35. Park, H.K. et al. 2011. Wip1 contributes to cell homeostasis maintained by the steady-state level of Wtp53. Cell Cycle 10: 2574-2582.
36. Zhang, J. & X. Chen. 2011. Novel role of Wip1 in p53-mediated cell homeostasis under non-stress conditions. Cell Cycle. 10: 3235.
37. Zhu, Y.H. & D.V. Bulavin. 2012. Wip1-dependent signaling pathways in health and diseases. Prog. Mol. Biol. Transl. Sci. 106: 307-325.
38. Lambros, M.B. et al. 2010. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod. Pathol. 23: 1334-1345.
39. Satoh, N. et al. 2011. Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival. Cancer Sci. 102: 1101-1106.
40. Wang, P. et al. 2011. Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas. J. Surg. Oncol. 104: 679-684.
41. Bulavin, D.V. et al. 2002. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet. 31: 210-215.
42. Li, J. et al. 2002. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat. Genet. 31: 133-134.
43. Hirasawa, A. et al. 2003. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin. Cancer Res. 9: 1995-2004.
44. Saito-Ohara, F. et al. 2003. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 63: 1876-1883.
45. Rauta, J. et al. 2006. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res. Treat. 95: 257-263.
46. Fuku, T. et al. 2007. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathol. Int. 57: 566-571.
47. Castellino, R.C. et al. 2008. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J. Neurooncol. 86: 245-256.
48. Tan, D.S. et al. 2009. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin. Cancer Res. 15: 2269-2280.
49. Belova, G.I. et al. 2005. Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biol. Ther. 4: 1154-1158.
50. Nannenga, B. et al. 2006. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol. Carcinog. 45: 594-604.
51. Bulavin, D.V. et al. 2004. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat. Genet. 36: 343-350.
52. Shreeram, S. et al. 2006. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J. Exp. Med. 203: 2793-2799.
53. Shreeram, S. et al. 2006. Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol. Cell 23: 757-764.
54. Fujimoto, H. et al. 2006. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ. 13: 1170-1180.
55. Yoda, A. et al. 2006. Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1. J. Biol. Chem. 281: 24847-24862.
56. Yoda, A. et al. 2008. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. J. Biol. Chem. 283: 18969-18979.
57. Carlessi, L. et al. 2010. A protein phosphatase feedback mechanism regulates the basal phosphorylation of Chk2 kinase in the absence of DNA damage. Biochim. Biophys. Acta. 1803: 1213-1223.
58. Lu, X. et al. 2007. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12: 342-354.
59. Zhang, X. et al. 2009. Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response. Cancer Res. 69: 7960-7968.
60. Pei, D., Y. Zhang & J. Zheng. 2012. Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget 3: 228-235.
61. Lu, X., T.A. Nguyen & L.A. Donehower. 2005. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Cell Cycle 4: 1060-1064.
62. Moon, S.H. et al. 2010. Dephosphorylation of gamma-H2AX by WIP1: an important homeostatic regulatory event in DNA repair and cell cycle control. Cell Cycle 9: 2092-2096.
63. Cha, H. et al. 2010. Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response. Cancer Res. 70: 4112-4122.
64. Macurek, L. et al. 2010. Wip1 phosphatase is associated with chromatin and dephosphorylates gammaH2AX to promote checkpoint inhibition. Oncogene. 29: 2281-2291.
65. Lu, X. et al. 2004. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol. Cell. 15: 621-634.
66. Nguyen, T.A. et al. 2010. The oncogenic phosphatase WIP1 negatively regulates nucleotide excision repair. DNA Repair. 9: 813-823.
67. Oh, K.S., M. Bustin, S.J. Mazur et al. 2011. UV-induced histone H2AX phosphorylation and DNA damage related proteins accumulate and persist in nucleotide excision repair-deficient XP-B cells. DNA Repair. 10: 5-15.
68. Takekawa, M. et al. 2000. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J. 19: 6517-6526.
69. Chuman, Y. et al. 2009. PPM1D430, a novel alternative splicing variant of the human PPM1D, can dephosphorylate p53 and exhibits specific tissue expression. J. Biochem. 145: 1-12.
70. Vivanco, I. & C.L. Sawyers. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2: 489-501.
71. Nicholson, K.M. & N.G. Anderson. 2002. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 14: 381-395.
72. Testa, J.R. & A. Bellacosa. 2001. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA 98: 10983-10985.
73. Kandel, E.S. & N. Hay. 1999. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 253: 210-229.
74. Cheng, J.Q. et al. 1992. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 89: 9267-9271.
75. Hu, P. et al. 1993. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol. Cell Biol. 13: 7677-7688.
76. West, K.A., S.S. Castillo & P.A. Dennis. 2002. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. 5: 234-248.
77. Datta, S.R., A. Brunet & M.E. Greenberg. 1999. Cellular survival: a play in three Akts. Genes Dev. 13: 2905-2927.
78. Shirai, T. et al. 1998. Specific detection of phosphatidylinositol 3, 4, 5-trisphosphate binding proteins by the PIP3 analogue beads: an application for rapid purification of the PIP3 binding proteins. Biochim. Biophys. Acta. 1402: 292-302.
79. Aman, M.J. et al. 1998. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J. Biol. Chem. 273: 33922-33928.
80. Alessi, D.R. et al. 1997. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 7: 261-269.
81. Alessi, D.R. et al. 1997. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr. Biol. 7: 776-789.
82. Sarbassov, D.D. et al. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22: 159-168.
83. Jacinto, E. et al. 2006. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137.
84. Datta, S.R. et al. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
85. Cardone, M.H. et al. 1998. Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321.
86. Brunet, A. et al. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
87. Kane, L.P. et al. 1999. Induction of NF-kappaB by the Akt/PKB kinase. Curr. Biol. 9: 601-604.
88. Romashkova, J.A. & S.S. Makarov. 1999. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401: 86-90.
89. Gesbert, F. et al. 2000. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J. Biol. Chem. 275: 39223-39230.
90. Rossig, L. et al. 2001. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol. Cell Biol. 21: 5644-5657.
91. Graff, J.R. et al. 2000. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 275: 24500-24505.
92. King, F.W. et al. 2004. Inhibition of Chk1 by activated PKB/Akt. Cell Cycle 3: 634-637.
93. Nave, B.T. et al. 1999. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344 Pt 2: 427-431.
94. Dan, H.C. et al. 2004. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 279: 5405-5412.
95. Ogawara, Y. et al. 2002. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 277: 21843-21850.
96. Zhou, B.P. et al. 2001. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3: 973-982.
97. Stambolic, V. et al. 2001. Regulation of PTEN transcription by p53. Mol. Cell 8: 317-325.
98. Mayo, L.D. et al. 2002. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277: 5484-5489.
99. Doll, R. & R. Peto. 1981. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Nat. Cancer Inst. 66: 1191.
100. Jang, M. et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
101. Byun, S. et al. 2010. Luteolin inhibits protein kinase C(epsilon) and c-Src activities and UVB-induced skin cancer. Cancer Res. 70: 2415-2423.
102. Weir, N.M. et al. 2007. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol. Ther. 6: 178-184.
103. Rezk, Y.A. et al. 2006. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am. J. Obstet Gynecol. 194: e23-e26.
104. Notarbartolo, M. et al. 2005. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett. 224: 53-65.
105. Comte, G. et al. 2001. C-Isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance. J. Med. Chem. 44: 763-768.